title: Correction of malnutrition and maldigestion with enzyme supplementation in patients with surgical suppression of exocrine pancreatic function.
abstract: We studied the occurrence and extent of malnutrition and maldigestion in 13 patients who underwent pancreatoduodenectomy (PD) and injection of Neoprene (polychloroprene) (NI) into the duct of Wirsung, which results in sclerosis of hte acinar pancreatic tissue, but spares the endocrine function. At discharge, patients under took an enzyme supplementation regimen with pancreatin (18, 00 United States Pharmacopoeia units of lipase per meal). Patients were rehospitalized 24.9 months after PD plus NI to undergo nutritional and metabolic evaluation (hospital control). Nutritional status was evaluated by measuring the serum albumin level, total iron binding capacity and total lymphocyte count. Digestive function was assessed by the D-xylose tolerance test and determination of fecal fat excretion. Patients were then discharged with pancrelipase, enteric-coated microspheres (ECM) supplementation (16,050 United States Pharmacopoeia units of lipase per meal). Malnutrition, defined as the occurrence of at least two abnormal nutritional parameters, was observed in six patients at hospital control. After six months on pancrelipase ECM, the nutritional status was re-evaluated in nine patients (three previously malnourished) who were all well nourished. The mean body weight was 84.7 per cent of usual body weight at discharge after PD plus NI and raised to 88.0 per cent at the hospital control (p less than 0.01) and to 93.7 per cent )p less than 0.05) after six months on pancrelipase ECM. At hospital control, results from the D-xylose test were normal in all patients, and steatorrhea dropped from 33.6 grams per day without enzyme supplementation to 15.3 grams per day with pancrelipase ECM (16,050 United States Pharmacopoeia units of lipase per meal). Steatorrhea was incompletely but satisfactorily corrected by pancrelipase ECM. On supplementation therapy with pancrelipase ECM, patients recover a good deal of the body weight and normalize the biochemical indices of malnutrition.
authors.affiliation: Scientific Institute, San Raffaele Hospital, Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Braga
authors.forename: M
authors.initials: M
authors.lastname: Cristallo
authors.forename: R
authors.initials: R
authors.lastname: De Franchis
authors.forename: A
authors.initials: A
authors.lastname: Mangiagalli
authors.forename: D
authors.initials: D
authors.lastname: Agape
authors.forename: M
authors.initials: M
authors.lastname: Primignani
authors.forename: V
authors.initials: V
authors.lastname: Di Carlo
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004063:Digestion / Q000187:drug effects; D004386:Duodenum / Q000601:surgery*; D005069:Evaluation Studies as Topic; D005260:Female; D006760:Hospitalization; D006801:Humans; D008049:Lipase / Q000627:therapeutic use*; D008286:Malabsorption Syndromes / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D009387:Neoprene / Q000008:administration & dosage; D009748:Nutrition Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009752:Nutritional Status; D010180:Pancreatectomy; D010184:Pancreatic Extracts / Q000627:therapeutic use*; D010194:Pancreatin / Q000627:therapeutic use; D020799:Pancrelipase; D011183:Postoperative Complications / Q000188:drug therapy* / Q000517:prevention & control; D012597:Sclerosing Solutions / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D010184:Pancreatic Extracts; D012597:Sclerosing Solutions; D020799:Pancrelipase; D010194:Pancreatin; D009387:Neoprene; D008049:Lipase